Older age and diclofenac are associated with increased risk of upper gastrointestinal bleeding in gout patients.

BACKGROUND

Gouty arthritis is a disease of global burden in which defective metabolism of uric acid causes arthritis. Gouty arthritis or medications used for its treatment may lead to uric acid-associated complications such as upper gastrointestinal bleeding (UGIB) and renal impairment.

METHODS

In this cross-sectional study with retrospective record review, 403 established gouty arthritis patients were recruited to determine the incidence of UGIB and associated factors among gout patients who were on regular nonsteroidal anti-inflammatory drugs (NSAIDs).

RESULTS

The mean age of the 403 gouty arthritis patients was 55.7 years old and the majority ( = 359/403; 89.1%) were male. The incidence of UGIB among gouty arthritis patients who were on NSAIDs was 7.2% ( = 29/403). Older age ( < 0.001), diclofenac medication ( = 0.003), pantoprazole medication ( = 0.003), end-stage renal failure (ESRF) ( = 0.007), smoking ( = 0.035), hypertension ( = 0.042) and creatinine ( = 0.045) were significant risk factors for UGIB among the gouty arthritis patients in univariable analysis. Older age ( = 0.001) and diclofenac medication ( < 0.001) remained significant risk factors for UGIB among the gouty arthritis patients in multivariable analysis.

CONCLUSIONS

Age and diclofenac were significantly associated with UGIB among patients with gouty arthritis on regular NSAIDs, indicating that these factors increased the risks of developing UGIB in gout patients. Hence, these high-risk groups of gouty arthritis patients should be routinely monitored to avoid the potential onset of UGIB. Our data also suggest that diclofenac should be prescribed for the shortest duration possible to minimize the risk of developing UGIB in gout patients.